DarioHealth (NASDAQ:DRIO) Share Price Crosses Below 200-Day Moving Average – Time to Sell?

DarioHealth Corp. (NASDAQ:DRIO)’s share price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $7.74 and traded as low as $6.80. DarioHealth shares last traded at $6.82, with a volume of 6,322 shares changing hands.

Analyst Upgrades and Downgrades

DRIO has been the topic of several research reports. Alliance Global Partners assumed coverage on DarioHealth in a research note on Wednesday, August 19th. They issued a “buy” rating and a $12.00 target price on the stock. TD Cowen lowered their price objective on DarioHealth from $11.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday, August 12th. Stifel Nicolaus reaffirmed a “buy” rating and set a $10.00 price objective on shares of DarioHealth in a report on Thursday, May 14th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a report on Friday, July 10th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

DarioHealth Stock Up 7.7%

The company has a current ratio of 2.31, a quick ratio of 1.92 and a debt-to-equity ratio of 0.56. The stock has a 50 day simple moving average of $7.18 and a 200 day simple moving average of $7.70. The firm has a market capitalization of $69.42 million, a PE ratio of -1.16 and a beta of 1.12.

DarioHealth (NASDAQ:DRIO) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.37. The company had revenue of $5.18 million during the quarter, compared to analyst estimates of $5.92 million. DarioHealth had a negative return on equity of 54.81% and a negative net margin of 169.87%. As a group, sell-side analysts forecast that DarioHealth Corp. will post -2.94 earnings per share for the current year.

Insider Transactions at DarioHealth

In other news, Director Dennis Matheis acquired 14,430 shares of the business’s stock in a transaction that occurred on Thursday, July 23rd. The stock was bought at an average price of $6.93 per share, with a total value of $99,999.90. Following the completion of the acquisition, the director directly owned 43,026 shares of the company’s stock, valued at approximately $298,170.18. The trade was a 50.46% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On DarioHealth

A number of hedge funds have recently modified their holdings of the company. Kestra Advisory Services LLC purchased a new stake in shares of DarioHealth in the fourth quarter worth about $35,000. Geode Capital Management LLC grew its holdings in DarioHealth by 167.9% during the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after purchasing an additional 31,063 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of DarioHealth in the second quarter worth approximately $249,000. XTX Topco Ltd lifted its position in shares of DarioHealth by 229.0% during the second quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after purchasing an additional 43,513 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in DarioHealth in the 2nd quarter valued at about $4,030,561. 33.39% of the stock is currently owned by institutional investors.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.